6.59 EFFECTS OF LONG-ACTING METHYLPHENIDATE ON NESFATIN-1 LEVELS IN MALE CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Objectives: Underlying pathophysiological mechanisms of appetite and weight loss or decreased rate of weight gain related with psychostimulants for the treatment of ADHD have not been fully clarified yet. Nesfatin-1, discovered in recent years, released by mainly hypothalamus, is a peptide responsible for the appetite regulation, weight loss and metabolic regulation. We aimed to investigate whether there is an association between nesfatin-1 and etiopathogenesis of ADHD, treatment response and metabolic side effects of MPH by comparing pre-and post-treatment serum levels of Nesfatin-1 in prepubertal boys with ADHD. Methods: 33 boys who were diagnosed with ADHD according to DSM IV-TR criterias in Bakirkoy Mental Health Research and Training Hospital, Child and Adolescent Psychiatry outpatient clinic, were included in the study. All participants were already applied to clinical interview and K-SADS. The appetite level of the patients was evaluated by Turkish version of Children's Eating Behaviour Questionnaire (CEBQ). ADHD symptoms were evaluated by Conners' Teacher and Parent Rating Scale. The patients' nesfatin-1 levels, biochemical metabolic parameters, anthropometric measures were determined before and after MPH treatment. Results: There was no significant change in serum Nesfatin-1 levels between pre-and post-treatment in the patient group. There were significant decreases in weight, body mass index (BMI), BMI percentile, waist circumferences (WC), WC percentiles of patients after the treatment. There was no significant correlation between Nesfatin-1 levels and BMI, BMI percentile, WC. Food responsiveness and enjoyment of food subscales scores and total scores of CEBQ after the treatment were significantly lower than the pretreatment levels. There was no significant correlation between serum nesfatin-1 level and the subscales of CEBQ both pre-and post-treatment except for the slowness in eating subscale of CEBQ. Conclusions: In light of the findings of our study, although MPH associated loss of appetite was observed, there was no clear evidence that this anorexic side effect is through Nesfatin directly. Although the variations in anthropometric body measures after the treatment was observed, there was no clear evidence that these changes could be related to direct effect of Nesfatin.